Satellos Bioscience Inc. (MSLE)
Satellos Bioscience Inc. (MSLE) tracked by StreetAlpha. It last closed at $5.68 on Nov 20, down 2.07% on the day.
Key Stats
Fiscal 2025Not reported for this period.
From MSLE's SEC filings, latest 40-F for the period ending Dec 31, 2025 (filed Mar 27). Per share figures are left out because the US listing can represent a different number of shares.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →- Every upgrade, downgrade and initiation as it happens
- Every price target change, raised or cut
- Consensus rating with the average, high and low targets
- Each firm's full rating history on MSLE
Technical AnalysisPrices may be delayed
The stock is 15% below its 20 day and 30% below its 50 day average. It is 44% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 33), near oversold. The nearest support is the swing low (Jun 5) at $5.62, and the nearest resistance the Pivot at $5.77.
| RSI (14) | 33.27 | Weak, oversold below 30 | Neutral |
| MACD | -0.37 | Below its signal line | Bearish |
| Stochastic | 6.2 | Near the bottom of its range | Oversold |
| ADX (14) | 22.8 | Weak trend | |
| Williams %R | -93.6 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -178.9 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −21.0% | Change over 10 sessions | Bearish |
| ATR (14) | $0.54 | Typical daily range, 9.4% of price |
| RSI (14) | 35.71 | Weak, oversold below 30 | Neutral |
| MACD | -0.55 | Below its signal line | Bearish |
| Stochastic | 12.6 | Near the bottom of its range | Oversold |
| ADX (14) | 15.5 | No clear trend | |
| Williams %R | -97.5 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -142.2 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −41.7% | Change over 10 sessions | Bearish |
| ATR (14) | $1.23 | Typical daily range, 21.7% of price |
What happened before
See how MSLE did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Whale Options FlowPrices may be delayed
90DNo whale options trades in MSLE in the last 90 days.
MSLE Institutional Ownership
Full report →- ●12 buying vs 12 selling
- ▲Shares held by funds +2.0%
- ▲Funds holding +4
- ▼Superinvestors: 1 added, 2 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 30 | 26 | +15.4% |
| In funds' top 10 | 1 | 0 | – |
| Held by funds | – | – | – |
| New / increased | 6 / 6 | 2 / 6 | +50.0% |
| Reduced / sold out | 10 / 2 | 7 / 7 | −14.3% |
| Put/call ratio | – | – | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether MSLE is in one of them and how their past MSLE trades turned out.
MSLE News Tone and PricePrices may be delayed
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered MSLE in an article yet. Here's the latest on the wider market.
- Condensed Consolidated Interim Financial Statements
- Satellos Changes Primary Efficacy Endpoint in BASECAMP Phase 2 Pediatric Trial to MRI-Measured Fat Fraction Following FDA Feedback
- Satellos to Host Investor Call to Provide an Update on Clinical and Regulatory Strategy for the BASECAMP Phase 2 Pediatric Study
- Satellos Establishes Scientific Advisory Board to Explore the Biology of Regeneration in Aging and Neuroscience
- Satellos to Participate in Upcoming Investor Conferences


